Dragon Pharmaceuticals Inc. announced today that it will proceed with a private placement of up to 4,000,000 units at US$2.00 per unit for total gross proceeds of up to US$8.0 million. Each unit consists of one Common Share in the Company and one Warrant to purchase an additional one-half Common Share at US$2.00 for a […]
Rita Jervis
CORPORATE CONTACT
Dragon Pharmaceuticals Inc.
Rita Jervis
Tel: (604) 669-8817
Email:
Dragon Signs EPO Marketing and Licensing Agreement for Taiwan
Dragon Pharmaceuticals Inc. (OTCBB – DRUG.OB) is pleased to announce that it has entered into a marketing and licensing agreement with Standard Chemical & Pharmaceutical Co., Ltd. (“Standard”) of Taiwan for the distribution of Dragon’s recombinant Erythropoietin (EPO). EPO has been the most effective drug for the treatment of severe anemia since its introduction in […]
Dragon Signs International Marketing and Licensing Agreement
Dragon Pharmaceuticals Inc. is pleased to announce that it has entered into a marketing and licensing agreement with Jelfa S.A. of Poland for the distribution of Erythropoietin (EPO), a blood growth protein used to treat anemia, in Central and Eastern Europe and the Commonwealth of Independent States (“CIS”). The agreement grants Jelfa, the second largest […]
Slow-Release EPO*
Industry analysts estimate the market for slow-release EPO at $5 billion per year, with application in the treatment of anemia in patients with kidney failure and cancer patients undergoing chemotherapy. In June 2000, Dragon acquired rights to a novel and patentable formulation for slow-release EPO by entering into a co-development agreement with Renapharm AB of […]
EPO
Our lead product, epoetin alpha injection (EPO), is an engineered form of a human protein, erythropoietin. This protein is naturally produced by the kidneys and stimulates the growth of red blood cells. When red blood cell counts are low, patients develop anemia which may require multiple blood transfusions and, in some cases, can lead to […]
G-CSF
Dragon is developing an engineered version of the naturally occurring granulocyte-colony stimulating factor, G-CSF. This human protein stimulates the bone marrow to produce neutrophils, a type of white blood cell or leukocyte. White blood cells help the body fight infection and disease and, when these cells are reduced in number (leukopenia), susceptibility to infection increases […]
Dragon Enters Phase II Clinical Trials for Additional EPO Applications
Dragon Pharmaceuticals Inc. is pleased to announce that it has been granted regulatory approval from the Chinese State Drug Administration (SDA) to enter Phase II clinical trials for two additional applications of the company’s lead product Erythropoietin (EPO). The efficacy of Dragon’s EPO, which stimulates the production of red blood cells, will be evaluated in […]
Dragon Pharmaceuticals Appoints Rita Jervis as VP Corporate Development
Dragon Pharmaceuticals Inc. is pleased to announce that it has appointed Ms. Rita Jervis as VP Corporate Development. Ms. Jervis will be responsible for leading the company’s strategic planning, business development, and investor relations initiatives. Ms. Jervis brings to her position 14 years of planning and operations experience in the biotechnology sector. In her position […]
EPO Orders for Over $1.3 Million in the International Markets Received
Dragon Pharmaceuticals is pleased to announce a number of significant developments in its international marketing of Erythropoietin (“EPO”) since its last international marketing update on October 6, 2000. Itaca Laboratories, Ltd., of Brazil, a licensee and distributor of the Company’s EPO has filed all requisite documents with Brazilian health authorities for the registration of EPO. […]
Dragon Announces Completion of US$7.0 Million Private Placement
Dragon Pharmaceuticals Inc. (“Dragon”) is pleased to announce the completion of its recent private placement of 3,500,000 units (the “Units”) at a price of US$2.00 per unit. Each Unit consists of one common share and one non-transferable share purchase warrant (the “Warrant”). Each Warrant entitles the holder to purchase one half common share at a […]
